Head-to-head evidence
Penpulimab vs Retifanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Penpulimab
Marketed by Akeso
NCT03866993 · Phase 3 · completed
This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment, with disease progression assessed by an independent radiology committee. Its primary endpoint, progression-free survival, was clearly met, roughly doubling median progression-free survival versus placebo plus chemotherapy.
Retifanlimab
Marketed by Incyte
NCT04205812 · Phase 3 · completed
Participants were randomly assigned and double-blinded to receive retifanlimab or placebo with standard chemotherapy, with 391 in the retifanlimab group and 192 in the control group. The hard clinical primary endpoint of overall survival was met, favoring retifanlimab (hazard ratio 0.75; p=0.0042).
Next expected readout: December 2027 · NCT07219576 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Penpulimab's landscape · Retifanlimab's landscape